Journal
ACTA PSYCHIATRICA SCANDINAVICA
Volume 146, Issue 3, Pages 251-257Publisher
WILEY
DOI: 10.1111/acps.13459
Keywords
antidepressants; antipsychotics; lithium; major depressive disorder; maintenance trial designs; mortality; psychiatric drug development
Categories
Ask authors/readers for more resources
Most psychiatric drugs have short-term effects on improving symptoms and do not provide long-term benefits for underlying diseases. A change in approach is needed in psychopharmacology practice and research, focusing on long-term disease modification.
Objective Drugs can be divided into two major categories, symptomatic and disease modifying. This review explores whether and how psychiatric drugs fall into one or the other of those categories, and the implications of those results for clinical practice and research in psychopharmacology. Method Narrative review. Results Most psychiatric drugs have only short-term effects of improving active symptoms. They do not show long-term benefits for the underlying disease, such as improving the course of illness and improving mortality. Evidence is provided for this claim in the treatment literature of antidepressants for depressive illness and antipsychotics for schizophrenia. Developing truly beneficial drugs for disease modification also is limited by the poor clinical and biological validity of Diagnostic and Statistical Manual diagnoses as well as the use of invalid falsely positive maintenance efficacy randomized discontinuation trial designs. Conclusions Current psychopharmacology is limited mostly to symptomatic effects, not transformative treatments for the diseases underlying those symptoms. A change in approach is needed in psychopharmacology practice and research, focusing on long-term disease modification rather than short-term symptom improvement.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available